Merrimack Pharmaceut (MACK) 6.32 $MACK
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), LGND: 113.74 (-1.34), ACOR: 27.07 (-0.45)
Merrimack Announces Positive Data on Oncology Candidate
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 3:57PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) announced results from the phase I study on pipeline candidate, MM-151.
MACK: 6.32 (-0.24), ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), PFE: 35.29 (-0.02)
Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in Multiple Solid Tumor Types, Including Colorectal Cancer
PR Newswire - Mon Jun 06, 6:30AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced results from the final analysis of the Phase 1 study of MM-151, a novel investigational oligoclonal epidermal growth factor receptor (EGFR) inhibitor, in patients with refractory solid tumors. These results were presented at a Poster Discussion Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
MACK: 6.32 (-0.24)
Merrimack/Baxalta Start Study on Colorectal Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri May 20, 1:37PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) and Baxalta Incorporated (BXLT) announced that the companies have initiated a phase I clinical study on pipeline candidate, MM-151.
MACK: 6.32 (-0.24), ABT: 38.40 (-0.47), PFE: 35.29 (-0.02), BXLT: 46.02 (-0.18)
Merrimack Announces a Leading-edge Biomarker-Selected, Multi-Arm Basket Trial that Matches Patients with Most Appropriate Combination Regimens
PR Newswire - Thu May 19, 6:05AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced today the initiation of a biomarker-selected, multi-arm Phase 1 clinical study in metastatic colorectal, non-small cell lung, and head and neck cancers. Merrimack's first-of-its-kind basket study will use a combination of genetic and nongenetic biomarkers to match patients to appropriate novel combinations of investigational drug regimens based on their cancer's molecular signature. This approach is expected to enable more than 95 percent of eligible patients to qualify for enrollment to one of the investigational arms of the study. Merrimack utilized its systems biology approach to identify the biomarkers and selection criteria of the study.
MACK: 6.32 (-0.24)
Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer
PR Newswire - Thu May 19, 6:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced the initiation of a Phase 1 clinical study of Merrimack's oligoclonal EGFR (epidermal growth factor receptor) inhibitor, MM-151, in combination with ONIVYDE® (irinotecan liposome injection) plus fluorouracil (5-FU) and leucovorin in patients with RAS wild-type metastatic colorectal cancer. Data from a prior Phase 1 study of MM-151 supports further clinical evaluation of the investigational therapy in patients with metastatic colorectal cancer. The initiation of this study advances the development path for ONIVYDE.
MACK: 6.32 (-0.24), BXLT: 46.02 (-0.18)
Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting
PR Newswire - Wed May 18, 4:10PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present on its extensive oncology pipeline at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016 at McCormick Place, Chicago, Illinois. Final results from a Phase 1 study evaluating the safety, pharmacology and initial efficacy of MM-151 will be presented in a Poster Discussion Session. Merrimack will also present on the results from its Phase 3 NAPOLI-1 study of ONIVYDE®, as well as on multiple therapeutic candidates from its antibody engineering and antibody-directed nanotherapeutic (ADN) technology platforms in six poster sessions.
MACK: 6.32 (-0.24)
Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series
PR Newswire - Tue May 17, 3:05PM CDT
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today presented an expanded analysis of its Phase 2 study of seribantumab (MM-121) in combination with exemestane in HER2-negative, hormone receptor positive metastatic breast cancer. Top line results from this study were announced in 2014. The final analysis, as well as a poster on Merrimack's investigational companion diagnostic for seribantumab, were presented this week at the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, in Miami, Florida.
MACK: 6.32 (-0.24)
Why Merrimack Pharmaceuticals' Stock Is Sliding Today
George Budwell, The Motley Fool - Motley Fool - Tue May 03, 10:22AM CDT
Image source: Pixabay. What : Merrimack Pharmaceuticals saw its shares drop by nearly 11% immediately after the opening bell today due to the company missing consensus for its total revenue in the first quarter of 2016. Specifically, Merrimack...
MACK: 6.32 (-0.24)
Merrimack (MACK) Posts Narrower-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:33AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 33 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of 39 cents and the prior-quarter loss of 41 cents.
MACK: 6.32 (-0.24), GILD: 84.45 (-1.32), AEGR: 1.37 (-0.13), BXLT: 46.02 (-0.18)
Merrimack reports 1Q loss
Automated Insights - Mon May 02, 3:15PM CDT
CAMBRIDGE, Mass. (AP) _ Merrimack Pharmaceuticals Inc. (MACK) on Monday reported a loss of $38.5 million in its first quarter.
MACK: 6.32 (-0.24)
Merrimack Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 02, 3:01PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its first quarter 2016 financial results. Merrimack will host a live conference call and webcast today, Monday, May 2 at 4:30 p.m., Eastern time, to provide an update on Merrimack's progress as well as a summary of these results.
MACK: 6.32 (-0.24)
Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:04AM CDT
The going has been quite satisfactory as we stand in the thick of the first earnings season of the year.
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), AERI: 18.59 (-0.22), AEGR: 1.37 (-0.13), PRTA: 46.52 (-0.89)
Merrimack (MACK) Q1 Earnings: What's Ahead for the Stock?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 6:06PM CDT
Merrimack (MACK) will report first-quarter 2016 earnings on May 2 after the market closes.
ZTS: 47.39 (-0.75), MACK: 6.32 (-0.24), AGIO: 50.35 (-5.87), LLY: 73.95 (-0.48)
Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting
PR Newswire - Thu Apr 21, 7:00AM CDT
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced positive data from preclinical studies evaluating MM-310, an antibody directed nanotherapeutic (ADN) that encapsulates a newly engineered form of the highly potent chemotherapy docetaxel as a prodrug in an ephrin receptor A2 (EphA2)-targeted liposome. Preclinical data on MM-310 were presented in an oral presentation and three poster sessions at the 2016 American Association for Cancer Research (AACR) Annual Meeting. The posters can be accessed on Merrimack's website.
MACK: 6.32 (-0.24)
Merrimack Announces Timing of First Quarter 2016 Investor Conference Call
PR Newswire - Wed Apr 20, 3:30PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its First Quarter 2016 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Monday, May 2.
MACK: 6.32 (-0.24)
Leica Biosystems and Merrimack Pharmaceuticals to Collaborate on Development of a Heregulin Companion Diagnostic for Seribantumab
PR Newswire - Thu Apr 14, 3:05PM CDT
Leica Biosystems and Merrimack Pharmaceuticals (NASDAQ: MACK) today announced a strategic partnership to develop companion diagnostic assays to aid in identification of patients who might best respond to current and future oncology therapies developed by Merrimack. The assays will be designed using Advanced Cell Diagnostics' (ACD's) RNAscope technology and will be processed on Leica Biosystems' BOND clinical advanced staining systems.
MACK: 6.32 (-0.24)
Zacks Investment Ideas feature highlights: Juno Therapeutics, Genocea Biosciences, Merrimack Pharmaceuticals and BioShares Biotechnology Clinical Trials ETF
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 8:30AM CDT
Zacks Investment Ideas feature highlights: Juno Therapeutics, Genocea Biosciences, Merrimack Pharmaceuticals and BioShares Biotechnology Clinical Trials ETF
MACK: 6.32 (-0.24), BBC: 19.82 (-0.54), GNCA: 3.94 (-0.28), JUNO: 42.98 (-2.55)
3 Biotech Stocks With Scary-High Debt-to-Capital Ratios
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 11, 7:40AM CDT
SOURCE: FLICKR USER GOTCREDIT.COM. Biotech companies pour millions of dollars into research programs that may or may not pan out, and money to fund that research can come from issuing stock or taking on debt. Debt isn't always a bad thing, but too...
SGYP: 3.97 (-0.03), MACK: 6.32 (-0.24), IRWD: 12.87 (-0.13), AMRN: 2.12 (-0.09)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), LGND: 113.74 (-1.34), ACOR: 27.07 (-0.45)
Merrimack Announces Positive Data on Oncology Candidate
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 3:57PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) announced results from the phase I study on pipeline candidate, MM-151.
MACK: 6.32 (-0.24), ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), PFE: 35.29 (-0.02)
Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in Multiple Solid Tumor Types, Including Colorectal Cancer
PR Newswire - Mon Jun 06, 6:30AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced results from the final analysis of the Phase 1 study of MM-151, a novel investigational oligoclonal epidermal growth factor receptor (EGFR) inhibitor, in patients with refractory solid tumors. These results were presented at a Poster Discussion Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
MACK: 6.32 (-0.24)
Merrimack/Baxalta Start Study on Colorectal Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri May 20, 1:37PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) and Baxalta Incorporated (BXLT) announced that the companies have initiated a phase I clinical study on pipeline candidate, MM-151.
MACK: 6.32 (-0.24), ABT: 38.40 (-0.47), PFE: 35.29 (-0.02), BXLT: 46.02 (-0.18)
Merrimack Announces a Leading-edge Biomarker-Selected, Multi-Arm Basket Trial that Matches Patients with Most Appropriate Combination Regimens
PR Newswire - Thu May 19, 6:05AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced today the initiation of a biomarker-selected, multi-arm Phase 1 clinical study in metastatic colorectal, non-small cell lung, and head and neck cancers. Merrimack's first-of-its-kind basket study will use a combination of genetic and nongenetic biomarkers to match patients to appropriate novel combinations of investigational drug regimens based on their cancer's molecular signature. This approach is expected to enable more than 95 percent of eligible patients to qualify for enrollment to one of the investigational arms of the study. Merrimack utilized its systems biology approach to identify the biomarkers and selection criteria of the study.
MACK: 6.32 (-0.24)
Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer
PR Newswire - Thu May 19, 6:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced the initiation of a Phase 1 clinical study of Merrimack's oligoclonal EGFR (epidermal growth factor receptor) inhibitor, MM-151, in combination with ONIVYDE® (irinotecan liposome injection) plus fluorouracil (5-FU) and leucovorin in patients with RAS wild-type metastatic colorectal cancer. Data from a prior Phase 1 study of MM-151 supports further clinical evaluation of the investigational therapy in patients with metastatic colorectal cancer. The initiation of this study advances the development path for ONIVYDE.
MACK: 6.32 (-0.24), BXLT: 46.02 (-0.18)
Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting
PR Newswire - Wed May 18, 4:10PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present on its extensive oncology pipeline at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016 at McCormick Place, Chicago, Illinois. Final results from a Phase 1 study evaluating the safety, pharmacology and initial efficacy of MM-151 will be presented in a Poster Discussion Session. Merrimack will also present on the results from its Phase 3 NAPOLI-1 study of ONIVYDE®, as well as on multiple therapeutic candidates from its antibody engineering and antibody-directed nanotherapeutic (ADN) technology platforms in six poster sessions.
MACK: 6.32 (-0.24)
Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series
PR Newswire - Tue May 17, 3:05PM CDT
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today presented an expanded analysis of its Phase 2 study of seribantumab (MM-121) in combination with exemestane in HER2-negative, hormone receptor positive metastatic breast cancer. Top line results from this study were announced in 2014. The final analysis, as well as a poster on Merrimack's investigational companion diagnostic for seribantumab, were presented this week at the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, in Miami, Florida.
MACK: 6.32 (-0.24)
Why Merrimack Pharmaceuticals' Stock Is Sliding Today
George Budwell, The Motley Fool - Motley Fool - Tue May 03, 10:22AM CDT
Image source: Pixabay. What : Merrimack Pharmaceuticals saw its shares drop by nearly 11% immediately after the opening bell today due to the company missing consensus for its total revenue in the first quarter of 2016. Specifically, Merrimack...
MACK: 6.32 (-0.24)
Merrimack (MACK) Posts Narrower-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:33AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 33 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of 39 cents and the prior-quarter loss of 41 cents.
MACK: 6.32 (-0.24), GILD: 84.45 (-1.32), AEGR: 1.37 (-0.13), BXLT: 46.02 (-0.18)
Merrimack reports 1Q loss
Automated Insights - Mon May 02, 3:15PM CDT
CAMBRIDGE, Mass. (AP) _ Merrimack Pharmaceuticals Inc. (MACK) on Monday reported a loss of $38.5 million in its first quarter.
MACK: 6.32 (-0.24)
Merrimack Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 02, 3:01PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its first quarter 2016 financial results. Merrimack will host a live conference call and webcast today, Monday, May 2 at 4:30 p.m., Eastern time, to provide an update on Merrimack's progress as well as a summary of these results.
MACK: 6.32 (-0.24)
Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:04AM CDT
The going has been quite satisfactory as we stand in the thick of the first earnings season of the year.
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), AERI: 18.59 (-0.22), AEGR: 1.37 (-0.13), PRTA: 46.52 (-0.89)
Merrimack (MACK) Q1 Earnings: What's Ahead for the Stock?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 6:06PM CDT
Merrimack (MACK) will report first-quarter 2016 earnings on May 2 after the market closes.
ZTS: 47.39 (-0.75), MACK: 6.32 (-0.24), AGIO: 50.35 (-5.87), LLY: 73.95 (-0.48)
Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting
PR Newswire - Thu Apr 21, 7:00AM CDT
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced positive data from preclinical studies evaluating MM-310, an antibody directed nanotherapeutic (ADN) that encapsulates a newly engineered form of the highly potent chemotherapy docetaxel as a prodrug in an ephrin receptor A2 (EphA2)-targeted liposome. Preclinical data on MM-310 were presented in an oral presentation and three poster sessions at the 2016 American Association for Cancer Research (AACR) Annual Meeting. The posters can be accessed on Merrimack's website.
MACK: 6.32 (-0.24)
Merrimack Announces Timing of First Quarter 2016 Investor Conference Call
PR Newswire - Wed Apr 20, 3:30PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its First Quarter 2016 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Monday, May 2.
MACK: 6.32 (-0.24)
Leica Biosystems and Merrimack Pharmaceuticals to Collaborate on Development of a Heregulin Companion Diagnostic for Seribantumab
PR Newswire - Thu Apr 14, 3:05PM CDT
Leica Biosystems and Merrimack Pharmaceuticals (NASDAQ: MACK) today announced a strategic partnership to develop companion diagnostic assays to aid in identification of patients who might best respond to current and future oncology therapies developed by Merrimack. The assays will be designed using Advanced Cell Diagnostics' (ACD's) RNAscope technology and will be processed on Leica Biosystems' BOND clinical advanced staining systems.
MACK: 6.32 (-0.24)
Zacks Investment Ideas feature highlights: Juno Therapeutics, Genocea Biosciences, Merrimack Pharmaceuticals and BioShares Biotechnology Clinical Trials ETF
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 8:30AM CDT
Zacks Investment Ideas feature highlights: Juno Therapeutics, Genocea Biosciences, Merrimack Pharmaceuticals and BioShares Biotechnology Clinical Trials ETF
MACK: 6.32 (-0.24), BBC: 19.82 (-0.54), GNCA: 3.94 (-0.28), JUNO: 42.98 (-2.55)
3 Biotech Stocks With Scary-High Debt-to-Capital Ratios
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 11, 7:40AM CDT
SOURCE: FLICKR USER GOTCREDIT.COM. Biotech companies pour millions of dollars into research programs that may or may not pan out, and money to fund that research can come from issuing stock or taking on debt. Debt isn't always a bad thing, but too...
SGYP: 3.97 (-0.03), MACK: 6.32 (-0.24), IRWD: 12.87 (-0.13), AMRN: 2.12 (-0.09)
